PAMI syndromeE83.2

Last updated on: 15.07.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

PAMI syndrome (PAMI is the acronym for "PSTPIP1- associated myeloid-related proteinemia inflammatory syndrome") is a recently described, rare (<50 patients are known) inflammatory disorder formerly known as"hyperzincemia/hypercalprotectinemia syndrome (Hz/Hc)". It is an autoinflammatory disorder characterized by:

a chronic systemic imflammation caused by:

The clinical picture should be distinguished from PAPA syndrome (pyogenic arthritis-pyoderma gangrenosum-acne syndrome).

Occurrence/EpidemiologyThis section has been translated automatically.

Prevalence: <1 / 1 000 000

EtiopathogenesisThis section has been translated automatically.

This is caused by mutations (p.E250K and p.E257K) in the PSTPIP1 gene.

ManifestationThis section has been translated automatically.

Infancy (age of onset: 13-30 months)

Clinical featuresThis section has been translated automatically.

Clinical manifestations include:

  • osteo-articular manifestations (80 %)
  • skin lesions(pyoderma gangraenosum; pyoderma gangraenosum-like skin lesions; hidranitis suppurativa: 71 %)
  • Splenomegaly (89 %)
  • hepatomegaly (68 %)
  • lymphadenopathy (42 %)
  • growth disturbances (58 %)
  • Hemorragic diasthesia with recurrent epistaxis and/or hematoma tendency (16%).

LaboratoryThis section has been translated automatically.

Mild to severe neutropenia and anemia (100%). Thrombocytopenia (42%). Signs of systemic inflammation (94%). Blood concentrations of zinc and MRP 8/14 (S100A8/A9) are significantly elevated.

TherapyThis section has been translated automatically.

Response to treatment varies, with no uniformly effective therapy. The most common treatment options are non-steroidal anti-inflammatory drugs, corticosteroids (n=9), anakinra (n=9), anti-TNF (n=6), and cyclosporine A (n=4)

Note(s)This section has been translated automatically.

Myeloid-related proteins (MRP) 8 (S100A8) and MRP14 (S100A9) are endogenous ligands of the Toll-like receptor (TLR) that are highly expressed in granulocytes, monocytes, and activated keratinocytes. Both proteins belong to the alarmin family, which are danger signals released in response to cellular stress or damage. Highly elevated serum concentrations of MRP8/14 complexes (calprotectin) have been found in patients with systemic juvenile idiopathic arthritis (SJIA) and familial Mediterranean fever (FMF; OMIM #249100).

LiteratureThis section has been translated automatically.

  1. Holzinger D et al. (2015) Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases. J Allergy Clin Immunol 136:1337-1345.
  2. Hashmi SK et al (2019) PSTPIP1-associated myeloid-related proteinemia inflammatory syndrome: A rare cause of childhood neutropenia associated with systemic inflammation and hyperzincemia. Pediatr Blood Cancer 66:e27439.
  3. Sampson B et al (2002) Hyperzincemia and hypercalprotectinemia: a new disorder of zinc metabolism. Lancet 360:1742-1745.
  4. Xu XM et al (2021) PAMI syndrome: A rare cause that can be easily misdiagnosed. Am J Med Genet A 185:3074-3082.

Last updated on: 15.07.2022